SCAI

This channel contains news about the Society for Cardiac Angiography and Interventions (SCAI), including coverage of its annual meeting and links to recently released practice guidelines. SCAI is a leading resource in interventional cardiology and cath lab techniques and technologies. 
 

Videos | Coronavirus (COVID-19) | May 06, 2021
Payam Dehghani, M.D.,  FRCPC, FACC, FSCAI, co-director of Prairie Vascular Research and associate professor at the...
Videos | Cath Lab | May 05, 2021
Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of...
The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  Christoper Baker, M.D., Hoag Memorial Hospital using the system. #SCAI21 #SCAI2021

The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  

Feature | Robotic Systems | May 05, 2021
May 5, 2021 — A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic...
Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.

Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.

News | Cardiovascular Business | May 05, 2021
May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI)...
One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

The key slide from the SCAI 2021 NACMI late-breaking presentation showing the very high adverse rates for COVID STEMI heart attack patients (red) as compared to pre-pandemic STEMI patient controls (green).

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial...
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for...
The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent.

News | Congenital Heart | May 01, 2021
May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for...
Videos | Structural Heart | April 30, 2021
Ashwin Nathan M.D., a cardiology fellow at the Hospital of the University of Pennsylvania, presented a late-breaking...
The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 

The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 

Feature | Structural Heart | April 30, 2021 | Dave Fornell, Editor
April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve (...
The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

Feature | Structural Heart | April 30, 2021
April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United...
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American...
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | April 29, 2021
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from...
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet...
The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

News | Radial Access | April 28, 2021 | Dave Fornell, Editor
April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to...
Videos | Cardiogenic Shock | April 28, 2021
William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit,...